80 related articles for article (PubMed ID: 18804493)
1. Effect of exendin-4 treatment upon glucose uptake parameters in rat liver and muscle, in normal and type 2 diabetic state.
Arnés L; Moreno P; Nuche-Berenguer B; Valverde I; Villanueva-Peñacarrillo ML
Regul Pept; 2009 Feb; 153(1-3):88-92. PubMed ID: 18804493
[TBL] [Abstract][Full Text] [Related]
2. Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states.
Moreno P; Nuche-Berenguer B; Gutiérrez-Rojas I; Acitores A; Sancho V; Valverde I; González N; Villanueva-Peñacarrillo ML
J Mol Endocrinol; 2012 Feb; 48(1):37-47. PubMed ID: 22065862
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle.
Arnés L; González N; Tornero-Esteban P; Sancho V; Acitores A; Valverde I; Delgado E; Villanueva-Peñacarrillo ML
Int J Mol Med; 2008 Jul; 22(1):127-32. PubMed ID: 18575785
[TBL] [Abstract][Full Text] [Related]
4. Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.
Ozyazgan S; Kutluata N; Afşar S; Ozdaş SB; Akkan AG
Pharmacology; 2005 Jun; 74(3):119-26. PubMed ID: 15746570
[TBL] [Abstract][Full Text] [Related]
5. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
[TBL] [Abstract][Full Text] [Related]
6. Amylin effect in extrapancreatic tissues participating in glucose homeostasis, in normal, insulin-resistant and type 2 diabetic state.
Moreno P; Acitores A; Gutiérrez-Rojas I; Nuche-Berenguer B; El Assar M; Rodriguez-Mañas L; Gomis R; Valverde I; Visa M; Malaisse WJ; Novials A; González N; Villanueva-Peñacarrillo ML
Peptides; 2011 Oct; 32(10):2077-85. PubMed ID: 21939703
[TBL] [Abstract][Full Text] [Related]
7. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models.
Villanueva-Peñacarrillo ML; Puente J; Redondo A; Clemente F; Valverde I
Endocrine; 2001 Jul; 15(2):241-8. PubMed ID: 11720253
[TBL] [Abstract][Full Text] [Related]
8. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle.
Alcántara AI; Morales M; Delgado E; López-Delgado MI; Clemente F; Luque MA; Malaisse WJ; Valverde I; Villanueva-Peñacarrillo ML
Arch Biochem Biophys; 1997 May; 341(1):1-7. PubMed ID: 9143346
[TBL] [Abstract][Full Text] [Related]
9. Characteristic of GLP-1 effects on glucose metabolism in human skeletal muscle from obese patients.
Villanueva-Peñacarrillo ML; Martín-Duce A; Ramos-Álvarez I; Gutiérrez-Rojas I; Moreno P; Nuche-Berenguer B; Acitores A; Sancho V; Valverde I; González N
Regul Pept; 2011 Jun; 168(1-3):39-44. PubMed ID: 21419173
[TBL] [Abstract][Full Text] [Related]
10. Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats.
Sancho V; Trigo MV; González N; Valverde I; Malaisse WJ; Villanueva-Peñacarrillo ML
J Mol Endocrinol; 2005 Aug; 35(1):27-38. PubMed ID: 16087719
[TBL] [Abstract][Full Text] [Related]
11. Preserved GLP-I effects on glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats.
Morales M; López-Delgado MI; Alcántara A; Luque MA; Clemente F; Márquez L; Puente J; Viñambres C; Malaisse WJ; Villanueva-Peñacarrillo ML; Valverde I
Diabetes; 1997 Aug; 46(8):1264-9. PubMed ID: 9231649
[TBL] [Abstract][Full Text] [Related]
12. Effects of selenium and exendin-4 on glucagon-like peptide-1 receptor, IRS-1, and Raf-1 in the liver of diabetic rats.
Barakat GM; Moustafa ME; Bikhazi AB
Biochem Genet; 2012 Dec; 50(11-12):922-35. PubMed ID: 22983684
[TBL] [Abstract][Full Text] [Related]
13. Prolonged exendin-4 administration stimulates pituitary-adrenocortical axis of normal and streptozotocin-induced diabetic rats.
Malendowicz LK; Neri G; Nussdorfer GG; Nowak KW; Zyterska A; Ziolkowska A
Int J Mol Med; 2003 Oct; 12(4):593-6. PubMed ID: 12964040
[TBL] [Abstract][Full Text] [Related]
14. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
15. Expression and purification of exendin-4, a GLP-1 receptor agonist, in Escherichia coli.
Yin X; Wei D; Yi L; Tao X; Ma Y
Protein Expr Purif; 2005 Jun; 41(2):259-65. PubMed ID: 15866711
[TBL] [Abstract][Full Text] [Related]
16. Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect.
Dhanesha N; Joharapurkar A; Shah G; Dhote V; Kshirsagar S; Bahekar R; Jain M
Pharmacol Rep; 2012; 64(1):140-9. PubMed ID: 22580530
[TBL] [Abstract][Full Text] [Related]
17. Exendin-4 improves hepatocyte injury by decreasing proliferation through blocking NGF/TrkA in diabetic mice.
Gezginci-Oktayoglu S; Sacan O; Yanardag R; Karatug A; Bolkent S
Peptides; 2011 Feb; 32(2):223-31. PubMed ID: 21055431
[TBL] [Abstract][Full Text] [Related]
18. GLP-1 effect upon the GPI/IPG system in adipocytes and hepatocytes from diabetic rats.
Márquez L; González N; Puente J; Valverde L; Villanueva-Peñacarrillo ML
Diabetes Nutr Metab; 2001 Oct; 14(5):239-44. PubMed ID: 11806463
[TBL] [Abstract][Full Text] [Related]
19. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states.
Nuche-Berenguer B; Moreno P; Portal-Nuñez S; Dapía S; Esbrit P; Villanueva-Peñacarrillo ML
Regul Pept; 2010 Jan; 159(1-3):61-6. PubMed ID: 19586609
[TBL] [Abstract][Full Text] [Related]
20. Effects of exendin-4 and selenium on the expression of GLP-1R, IRS-1, and preproinsulin in the pancreas of diabetic rats.
Barakat G; Moustafa ME; Khalifeh I; Hodroj MH; Bikhazi A; Rizk S
J Physiol Biochem; 2016 Aug; 73(3):387-394. PubMed ID: 28589533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
